September 20, 2021
Article
In a study presented at the 2021 AUA annual meeting, Bilal Chughtai, MD, and co-authors implemented the new iTind system, designed to treat patients with LUTS secondary to BPH by implanting the device via a cystoscopic procedure.
In this interview, Steven A. Kaplan, MD, discusses notable findings from a recent study evaluating multiple BPH treatments as well as his own patient selection process for treatments.
September 19, 2021
Video
“The Zenflow device is certainly something that…appears to be able to be placed quite easily, seems to be minimally invasive [and] so far seems to be durable,” says Peter Chin, MD.
September 17, 2021
In a study presented at the 2021 AUA Annual Meeting, Andrew Higgins, MD, and co-authors implemented electrocautery protocols to mitigate blood loss among patients who undergo Aquablation.
September 16, 2021
“My patient selection process for BPH treatments can be a little bit cumbersome and take time, but that's really because for the first time ever, we have so many different options available to men,” says Dean Elterman, MD, MSc, FRCSC.
September 15, 2021
“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.
September 14, 2021
“For some men, it's very important to make sure that they have an antegrade ejaculation and this is a treatment modality that we're able to offer them,” says Andrew Higgins, MD.
“What's novel about the iTind system is [that] it's one of the first treatments that [can] be deployed through a flexible cystoscope, as well as the fact that there is no permanent energy or permanent foreign body that's left within the prosthetic urethra,” says Bilal Chughtai, MD.
September 10, 2021
In this interview, Dean Elterman, MD, discusses Rezum and Aquablation abstracts he presented at the 2021 AUA Annual Meeting and provides his overall perspective on the treatment of BPH.
September 07, 2021
Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.
